NCT06540846 Deep Learning for Histopathological Classification and Prognostication of Gynaecologic Smooth Muscle Tumours
| NCT ID | NCT06540846 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Bergonié |
| Condition | Stump |
| Study Type | OBSERVATIONAL |
| Enrollment | 392 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 392 participants in total. It began in 2023-12-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Smooth muscle tumors of the uterus that do not fit the diagnostic criteria of benignity (such as leiomyomas) or malignancy (such as leiomyosarcomas) are called STUMP (smooth muscle tumor of uncertain malignant potential). A potential solution to this problem could be the application of predictive models using artificial intelligence (AI) to aid in the histopathological classification and prognosis of gynecological smooth muscle tumors. Deep learning using convolutional neural networks represents a specific class of machine learning, in which predictive models are trained by considering small groups of pixels in digital images and iteratively identifying salient features. In this study, we aim to develop deep learning models capable of accurately subclassifying and predicting the prognosis of gynecological smooth muscle tumors, based on histopathological features of hematoxylin and eosin (H\&E) slides. The aim is to develop a diagnostic and prognostic algorithm to help pathologists better classify and diagnose uterine smooth muscle tumors and predict their clinical course.
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of uterine smooth muscle tumors (leiomyomas, smooth muscle tumors of uncertain malignancy and leiomyosarcomas), registered in the RRePS database and/or treated at Institut Bergonié or one of the participating centers. * Histopathological material available (kerosene blocks and/or slides). * The follow-up (outcome) is required for each LMS/ STUMP. Exclusion Criteria: * na
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06540846 clinical trial?
This trial is open to female participants only, studying Stump. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06540846 currently recruiting?
Yes, NCT06540846 is actively recruiting participants. Contact the research team at s.croce@bordeaux.unicancer.fr for enrollment information.
Where is the NCT06540846 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT06540846 clinical trial?
NCT06540846 is sponsored by Institut Bergonié. The trial plans to enroll 392 participants.